Breast Cancer Clinical Trial
Official title:
Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers
RATIONALE: Learning about the long-term effects of tamoxifen and ovarian function
suppression on brain function may help doctors plan cancer treatment.
PURPOSE: This study is looking at brain function in premenopausal women who are receiving
tamoxifen with or without ovarian function suppression for early-stage breast cancer on
clinical trial IBCSG-2402.
OBJECTIVES:
Primary:
- To evaluate and compare changes in cognitive function over 1 year in premenopausal
breast cancer patients who receive adjuvant tamoxifen with or without ovarian function
suppression (OFS).
Secondary:
- To compare the effect of tamoxifen with OFS versus exemestane with OFS on cognitive
function over 1 year.
- To compare the effect of tamoxifen alone versus exemestane with OFS on cognitive
function over 1 year.
- To evaluate and compare changes in cognitive function over 5 years and 6 years between
the 3 treatment groups (pending funding becoming available for the year 5 and 6
measures) on clinical trial IBCSG-2402.
- To explore the impact of receiving or not receiving prior chemotherapy on changes in
cognitive function.
- To explore the relationship between subjective and objective cognitive function.
- To explore the relationship between cognitive function, psychological distress,
fatigue, insomnia, and quality of life.
OUTLINE: This is a multicenter study.
Patients undergo objective cognitive function assessment over 20-25 minutes, using the
CogState computerized test battery, which consists of five tasks that measure the speed of
psychomotor function, visual attention, working memory and the accuracy of working memory,
learning and memory and executive function (all non-verbal). They undergo subjective
cognitive function assessment, using the Cognitive Failures Questionnaire (CFQ), a 25-item
self-report measure that assesses a person's failures in memory, perception, and motor
function over the past 6 months. Patients also complete General Health Questionnaire -12
(measuring psychologic distress), Brief Fatigue Inventory, NCI Common Terminology Criteria
for Adverse Events, and a patient-rated linear analogue self-assessment (LASA) scale
measuring insomnia. Patients complete these assessments at baseline (after registration to
clinical trial IBCSG-2402, but before beginning protocol therapy) and at 1, 5, and 6 years
after randomization on IBCSG-2402.
Relevant clinical factors, such as age, adjuvant chemotherapy, co-morbidity and concomitant
medications are assessed. In addition, language, education, psychiatric and neurological
history, alcohol consumption and right/left handedness are also assessed.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |